Showing results (81-90 of 119) with videos related to
Sort By:
Pageof 12
Tijdschrift Voor Kindergeneeskunde|April 1, 1988
[Results of treatment of children with acute lymphatic leukemia (ALL) according to the ALL V protocol of the Netherlands Working Group on Leukemia in Children]A van der Does-van den Berg, E R van Wering, S Suciu, et al.European Journal of Cancer (Oxford, England : 1990)|February 16, 2000
Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia? An analysis of the AML 8A Study of the Leukemia Cooperative Group of the EORTC and GIMEMA. European Organization for Research and Treatment of Cancer (EORTC) Leukemia Cooperative Group and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA)S Keating, T de Witte, S Suciu, et al.The Journal of Urology|September 1, 1986
A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of CancerP H Smith, S Suciu, M R Robinson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative GroupR Zittoun, S Suciu, F Mandelli, et al.European Journal of Cancer (Oxford, England : 1990)|October 7, 2006
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma GroupC J A Punt, S Suciu, M A Gore, et al.Medical and Pediatric Oncology|March 1, 1996
Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872C Béhar, S Suciu, Y Benoit, et al.Leukemia|September 10, 2005
Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative GroupH Zwierzina, S Suciu, J Loeffler-Ragg, et al.Annals of Hematology|April 1, 2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)R Willemze, S Suciu, P Muus, et al.European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanomaT Kivelä, S Suciu, J Hansson, et al.British Journal of Haematology|February 15, 2002
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914)P Sonneveld, S Suciu, P Weijermans, et al.Pageof 12